Parkinson’s LRRK2 drug fails pivotal trial, dimming hopes for broad therapy
TL;DR Summary
Biogen and Denali Therapeutics' experimental Parkinson’s drug targeting the LRRK2 protein did not slow disease progression in a large randomized trial, delivering a setback to the idea that LRRK2 blockade could benefit all patients with Parkinson’s disease.
- Closely watched experimental Parkinson’s drug fails key clinical trial statnews.com
- Biogen axes Denali-partnered Parkinson’s drug after phase 2 flop Fierce Biotech
- Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease Biogen
- Biogen, Denali to drop drug in non-genetic Parkinson’s after mid-stage study flop Endpoints News
- BIIB122 fails to slow motor decline in early Parkinson’s disease trial The Clinical Trial Vanguard
Reading Insights
Total Reads
0
Unique Readers
8
Time Saved
2 min
vs 3 min read
Condensed
91%
432 → 37 words
Want the full story? Read the original article
Read on statnews.com